Outcome of the Meeting of Board of Directors held on Monday, February 09, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Genpharmasec Limited approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with the limited review report by the auditor Bilimoria Mehta & Co. On a standalone basis, profit after tax for the nine months stood at around Rs. 313.15 lakhs versus Rs. 267.30 lakhs in the same period last year, with Q3 standalone PAT at about Rs. 75.64 lakhs. On a consolidated basis, the company slipped into a loss for the nine-month period (PBT of approx. Rs. (88.21) lakhs), dragged down by the newly acquired subsidiary Derren Healthcare Private Limited, which posted a net loss of around Rs. 304.41 lakhs for the period, and by losses in the Laboratory Testing and Manufacturing & Processing segments. The company also completed the 70% acquisition of Derren Healthcare on July 25, 2025, making it a subsidiary, and reclassified certain equity shares from Inventories to Financial Investments at fair value through OCI, with a retrospective decrease in inventories of Rs. 89.32 lakhs.
Shareholders should note the mixed picture: standalone profitability has improved year-on-year, but the consolidated picture has turned negative largely because of the newly consolidated subsidiary's losses and weak performance in the non-pharma segments. The change in auditor from Abhishek S Tiwari & Associates to Bilimoria Mehta & Co. and the retrospective reclassification of equity shares are accounting-level changes that should be tracked for any impact on future reported numbers.